# Cryoport, Inc.: overview

CYRX · Nasdaq · CIK 1124524 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cyrx.md) · [Financials](/companies/cyrx/financials.md) · [Filings](/companies/cyrx/filings.md) · [Insiders](/companies/cyrx/insiders.md)

Latest reported revenue: [$49.0m](/filings/0001104659-26-092107.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-092107).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [38.3](/filings/0001104659-25-107640.md) | [41.5 d](/filings/0001104659-26-024180.md) | [41.0](/filings/0001104659-26-055513.md) | [45.5](/filings/0001104659-26-092107.md) | [44.2](/filings/0001104659-25-107640.md) | [45.5 d](/filings/0001104659-26-024180.md) | [47.8](/filings/0001104659-26-055513.md) | [49.0](/filings/0001104659-26-092107.md) |
| Gross margin | % | [45.5%](/filings/0001104659-25-107640.md) | [47.0% d](/filings/0001104659-26-024180.md) | [45.4%](/filings/0001104659-26-055513.md) | [47.0%](/filings/0001104659-26-092107.md) | [48.2%](/filings/0001104659-25-107640.md) | [47.8% d](/filings/0001104659-26-024180.md) | [45.8%](/filings/0001104659-26-055513.md) | [46.6%](/filings/0001104659-26-092107.md) |
| Operating margin | % | [(34.9%)](/filings/0001104659-25-107640.md) | [(30.7%) d](/filings/0001104659-26-024180.md) | [(17.5%)](/filings/0001104659-26-055513.md) | [(21.2%)](/filings/0001104659-26-092107.md) | [(22.5%)](/filings/0001104659-25-107640.md) | [(22.1%) d](/filings/0001104659-26-024180.md) | [(20.1%)](/filings/0001104659-26-055513.md) | [(20.5%)](/filings/0001104659-26-092107.md) |
| Net margin | % | [2.1%](/filings/0001104659-25-107640.md) | [(45.1%) d](/filings/0001104659-26-024180.md) | [(29.2%)](/filings/0001104659-26-055513.md) | [239.5%](/filings/0001104659-26-092107.md) | [(15.7%)](/filings/0001104659-25-107640.md) | [(25.6%) d](/filings/0001104659-26-024180.md) | [(22.1%)](/filings/0001104659-26-055513.md) | [(16.9%)](/filings/0001104659-26-092107.md) |
| Diluted EPS | $ per share | [(0.02)](/filings/0001104659-25-107640.md) | not reported | [(0.28)](/filings/0001104659-26-055513.md) | [2.13](/filings/0001104659-26-092107.md) | [(0.18)](/filings/0001104659-25-107640.md) | not reported | [(0.25)](/filings/0001104659-26-055513.md) | [(0.20)](/filings/0001104659-26-092107.md) |
| Free cash flow | $m | [(3.8) d](/filings/0001104659-25-107640.md) | [(10.7) d](/filings/0001104659-26-024180.md) | [(7.5)](/filings/0001104659-26-055513.md) | [(11.7) d](/filings/0001104659-26-092107.md) | [(1.3) d](/filings/0001104659-25-107640.md) | [(4.5) d](/filings/0001104659-26-024180.md) | [(6.2)](/filings/0001104659-26-055513.md) | [(8.0) d](/filings/0001104659-26-092107.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [223](/filings/0001558370-24-003128.md) | [237](/filings/0001558370-25-002509.md) | [169](/filings/0001104659-26-024180.md) | [157](/filings/0001104659-26-024180.md) | [176](/filings/0001104659-26-024180.md) |
| Gross margin | % | [43.4%](/filings/0001558370-24-003128.md) | [43.8%](/filings/0001558370-25-002509.md) | [44.7%](/filings/0001104659-26-024180.md) | [44.4%](/filings/0001104659-26-024180.md) | [47.1%](/filings/0001104659-26-024180.md) |
| Operating margin | % | [(8.0%)](/filings/0001558370-24-003128.md) | [(13.4%)](/filings/0001558370-25-002509.md) | [(59.6%)](/filings/0001104659-26-024180.md) | [(77.6%)](/filings/0001104659-26-024180.md) | [(20.9%)](/filings/0001104659-26-024180.md) |
| Net margin | % | [(123.8%)](/filings/0001558370-24-003128.md) | [(15.7%)](/filings/0001558370-25-002509.md) | [(59.0%)](/filings/0001104659-26-024180.md) | [(73.2%)](/filings/0001104659-26-024180.md) | [44.4%](/filings/0001104659-26-024180.md) |
| Diluted EPS | $ per share | [(6.18)](/filings/0001558370-24-003128.md) | [(0.93)](/filings/0001558370-25-002509.md) | [(2.21)](/filings/0001104659-26-024180.md) | [(2.49)](/filings/0001104659-26-024180.md) | [1.40](/filings/0001104659-26-024180.md) |
| Free cash flow | $m | [(15.8)](/filings/0001558370-24-003128.md) | [(24.0)](/filings/0001558370-25-002509.md) | [(39.5)](/filings/0001104659-26-024180.md) | [(33.6)](/filings/0001104659-26-024180.md) | [(25.0)](/filings/0001104659-26-024180.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cyrx/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2021-11-16 | [Blackstone Holdings II L.P.](/insiders/1484870.md) | 10% owner | Sale (S) | 11,400 | $76.00 | $866.4k | [Form 4](/filings/0000899243-21-045284.md) |
| 2021-11-16 | [Blackstone Holdings II L.P.](/insiders/1484870.md) | 10% owner | Sale (S) | 488,600 | $76.00 | $37.1m | [Form 4](/filings/0000899243-21-045284.md) |
| 2021-08-24 | [Blackstone Holdings II L.P.](/insiders/1484870.md) | 10% owner | Sale (S) | 7,638 | $60.00 | $458.3k | [Form 4](/filings/0000899243-21-034284.md) |
| 2021-08-24 | [Blackstone Holdings II L.P.](/insiders/1484870.md) | 10% owner | Sale (S) | 327,362 | $60.00 | $19.6m | [Form 4](/filings/0000899243-21-034284.md) |
| 2021-06-15 | [Blackstone Holdings II L.P.](/insiders/1484870.md) | 10% owner | Sale (S) | 4,560 | $60.00 | $273.6k | [Form 4](/filings/0000899243-21-024555.md) |
| 2021-06-15 | [Blackstone Holdings II L.P.](/insiders/1484870.md) | 10% owner | Sale (S) | 195,440 | $60.00 | $11.7m | [Form 4](/filings/0000899243-21-024555.md) |
| 2021-06-09 | [Blackstone Holdings II L.P.](/insiders/1484870.md) | 10% owner | Sale (S) | 11,401 | $60.00 | $684.1k | [Form 4](/filings/0000899243-21-023351.md) |
| 2021-06-09 | [Blackstone Holdings II L.P.](/insiders/1484870.md) | 10% owner | Sale (S) | 488,599 | $60.00 | $29.3m | [Form 4](/filings/0000899243-21-023351.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $66.2m | 4,218,434 |  | Added +237,536 |
| [CADIAN CAPITAL MANAGEMENT, LP](/funds/1423686.md) | 2026-06-30 | $45.9m | 2,920,681 |  | Reduced −1,855,662 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $35.7m | 2,276,741 |  | Reduced −2,299,989 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $33.8m | 2,151,943 |  | Added +33,087 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $27.1m | 1,724,726 |  | Reduced −1,245,738 |
| [FRED ALGER MANAGEMENT, LLC](/funds/3520.md) | 2026-06-30 | $24.3m | 1,545,293 |  | Reduced −154,086 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $23.3m | 1,482,500 | Call | Added +736,900 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $20.6m | 1,312,370 |  | Added +64,235 |
| [MAK CAPITAL ONE LLC](/funds/1385702.md) | 2026-06-30 | $20.1m | 1,277,359 |  | Reduced −145,906 |
| [First Eagle Investment Management, LLC](/funds/1325447.md) | 2026-06-30 | $20.0m | 1,271,424 |  | Added +526,575 |

## Recent filings

[All 985 filings](/companies/cyrx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 17:03 ET | [10-Q](/filings/0001104659-26-092107.md) | Quarterly report, period 2026-06-30 | 0001104659-26-092107 |
| 2026-08-06 | 16:30 ET | [8-K](/filings/0001104659-26-092064.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-092064 |
| 2026-06-09 | 17:00 ET | [8-K](/filings/0001104659-26-071892.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-071892 |
| 2026-05-05 | 14:36 ET | [10-Q](/filings/0001104659-26-055513.md) | Quarterly report, period 2026-03-31 | 0001104659-26-055513 |
| 2026-05-04 | 16:30 ET | [8-K](/filings/0001104659-26-054942.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-054942 |
| 2026-04-22 | 16:30 ET | [DEF 14A](/filings/0001140361-26-016129.md) | Proxy statement, period 2026-06-05 | 0001140361-26-016129 |
| 2026-03-05 | 16:53 ET | [10-K](/filings/0001104659-26-024180.md) | Annual report, period 2025-12-31 | 0001104659-26-024180 |
| 2026-03-03 | 17:10 ET | [8-K](/filings/0001104659-26-022940.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-022940 |
| 2025-11-06 | 14:33 ET | [10-Q](/filings/0001104659-25-107640.md) | Quarterly report, period 2025-09-30 | 0001104659-25-107640 |
| 2025-11-04 | 17:18 ET | [8-K](/filings/0001104659-25-106421.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-106421 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-024180.md), filed Mar 5, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/8d35430f-f319-4a7f-9b62-5189ece9ba23)

## About the filer

- CIK: 1124524
- Tickers: CYRX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: NV
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.